Cargando…

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience

Women with endometrial cancer (EC) frequently receive adjuvant paclitaxel and carboplatin (PC) chemotherapy. There is no standard first line chemotherapy at disease recurrence. Data extrapolated from ovarian cancer has suggested that patients with recurrent EC may benefit from further platinum-based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubinstein, Maria, Halpenny, Darragh, Makker, Vicky, Grisham, Rachel N., Aghajanian, Carol, Cadoo, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461565/ https://www.ncbi.nlm.nih.gov/pubmed/31011610 http://dx.doi.org/10.1016/j.gore.2019.04.002

Ejemplares similares

Caregivers Clinic at Memorial Sloan Kettering Cancer Center
por: Applebaum, Allison
Publicado: (2021)

Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center
por: Lidsky, Michael E., et al.
Publicado: (2018)

Brain metastasis in advanced serous borderline tumor of the ovary: A case presentation()
por: Martin, Madhuri, et al.
Publicado: (2017)

The Memorial Sloan Kettering Prognostic Score: Correlation with survival in patients with advanced gastric cancer
por: Wan, Mingyu, et al.
Publicado: (2023)

Integrative Cancer Care in a US Academic Cancer Centre: The Memorial Sloan–Kettering Experience
por: Deng, G.
Publicado: (2008)

Memorial Sloan-Kettering Cancer Center: Two Decades of Experience with Ductal Carcinoma In Situ of the Breast
por: Choi, Daniel Xavier, et al.
Publicado: (2012)

Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
por: Bazzi, Wassim M., et al.
Publicado: (2014)

Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
por: Soff, Gerald A., et al.
Publicado: (2019)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
por: Tzeng, Michael, et al.
Publicado: (2021)

Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification
por: Choong, Caroline Victoria, et al.
Publicado: (2011)

Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram
por: Oses, Gabriela, et al.
Publicado: (2023)

Thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis (FAP): Memorial Sloan-Kettering Cancer Center (MSKCC) registry experience
por: Markowitz, Arnold J, et al.
Publicado: (2011)

Management of Locally Advanced Rectal Cancer During The COVID-19 Pandemic: A Necessary Paradigm Change at Memorial Sloan Kettering Cancer Center
por: Romesser, Paul B., et al.
Publicado: (2020)

External validation of Memorial Sloan Kettering Cancer Center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer
por: Milonas, Daimantas, et al.
Publicado: (2020)

The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria
por: Tamada, Satoshi, et al.
Publicado: (2018)

The association between Memorial Sloan Kettering Frailty Index with 30-day survival among patients aged ≥ 75 with cancer and COVID-19
por: Kim, Soo Jung, et al.
Publicado: (2022)

Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience
por: Page, David B, et al.
Publicado: (2014)

Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model
por: Bamias, Aristotelis, et al.
Publicado: (2010)

Validation of the Memorial Sloan-Kettering Cancer Center Nomogram to Predict Disease-Specific Survival after R0 Resection in a Chinese Gastric Cancer Population
por: Chen, Donglai, et al.
Publicado: (2013)

Validation of the Memorial Sloan Kettering Cancer Center nomogram for predicting non-sentinel lymph node metastasis in sentinel lymph node-positive breast-cancer patients
por: Bi, Xiang, et al.
Publicado: (2015)

Impact of the Discordance Between Scales of Memorial Sloan-Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium in Patients’ Prognosis With Metastatic Renal Cancer
por: Grimaldo-Roque, Hiram Josue, et al.
Publicado: (2022)

Antiproliferative Effects of the Methanolic Petiole Extract of Eichhornia crassipes Against Sloan Kettering Melanoma 5 Cell Line: An In Vitro Study
por: P, Noufal K, et al.
Publicado: (2022)

Evaluation of Memorial Sloan‐Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma
por: Jahr, Guro, et al.
Publicado: (2018)

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
por: Shen, Sherry, et al.
Publicado: (2021)

PB.3. Detection of lymph node metastases in newly diagnosed breast cancer patients with axillary ultrasonography in combination with the Memorial Sloan Kettering Cancer Centre normogram as a prediction tool
por: Low, CS, et al.
Publicado: (2014)

Validation of the Memorial Sloan Kettering Cancer Center nomogram to predict disease-specific survival in a Chinese gastric cancer population receiving postoperative chemoradiotherapy after an R0 resection
por: Zhou, Meng-long, et al.
Publicado: (2016)

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
por: Rubinstein, Maria M., et al.
Publicado: (2023)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system
por: Kim, Sehui, et al.
Publicado: (2016)

Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis
por: Rodrigues da Cunha Colombo Bonadio, Renata, et al.
Publicado: (2018)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
por: You, Maojin, et al.
Publicado: (2023)

Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma: Model development and external validation with Memorial Sloan Kettering Cancer Center model and the international metastatic renal cell carcinoma database consortium model
por: Shin, Dongrul, et al.
Publicado: (2021)

The Sloane Project
por: Bishop, H
Publicado: (2004)

T. George Sloan
Publicado: (1895)

John Sloan
Publicado: (1918)

Samuel Sloan
Publicado: (1920)

Archibald Sloan
Publicado: (1923)

William Sloan
Publicado: (1909)

Sloane Deaf
por: Payne, C. M. E. Rowland
Publicado: (1985)

Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma
por: Fujiwara, Kazuko, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_tmqoqcju6p7pekuomn9ht020u9